Skip to content
  • Tuesday, 16 June 2026
  • 2:58 pm
  • Follow Us
Lab DB
  • Home
  • About Us
    • About Us
    • Affiliate Disclosure
    • Cookie Policy
    • Disclaimer
    • Privacy Policy
    • DMCA
    • Terms of Service
  • Contact Us
  • FAQ
  • Home
  • AvenCell Therapeutics Unveils Promising Early Data for Switchable Allogeneic CAR-T Therapy in Relapsed/Refractory AML at EHA 2026
Pharmaceutical R&D

AvenCell Therapeutics Unveils Promising Early Data for Switchable Allogeneic CAR-T Therapy in Relapsed/Refractory AML at EHA 2026

Teuku Ryan Jun 16, 2026 0

AvenCell Therapeutics presented updated results for its CAR-T cell blood cancer therapy at EHA 2026. The European Hematology Association (EHA)…

Read More
Rubedo turns a senescence-targeting drug on precancerous skin, and sees an efficacy signal without the intense rednessPaternal Age and the Evolutionary Advantage of Harmful Sperm Mutations: A Comprehensive Analysis of Genetic Risks to Future GenerationsStandard Model Reinforced as New Muon Calculations Resolve Decades of Physics DiscrepanciesScience News: Empowering Public Understanding of Science, Medicine, and Technology Since 1921
MEDVi Under Scrutiny: AI-Powered Telehealth Startup Faces FDA Warnings, Deceptive Marketing Allegations, and Multiple Lawsuits Despite Meteoric GrowthLLMOps in 2026: The 10 Tools Every Team Must HaveHigh-Dimensional Topological Structures Discovered in Entangled Photons Offer New Framework for Quantum Information StabilityWater-in-Diesel Emulsion Technology Offers Significant Emissions Reduction Potential Without Engine Modification
Professor Peter Tessier Pioneers AI-Driven Solutions for Antibody Deliverability ChallengesSalesforce lands 140 life sciences clients, pitches ‘headless’ AI to pharmaEngineered Metamaterials Breakthrough Unlocks Precision Control of Heat Transfer at the NanoscaleAvenCell Therapeutics Unveils Promising Early Data for Switchable Allogeneic CAR-T Therapy in Relapsed/Refractory AML at EHA 2026
YOU MAY HAVE MISSED
Biotech & Genetic Research
Professor Peter Tessier Pioneers AI-Driven Solutions for Antibody Deliverability Challenges
Jia Lissa Jun 16, 2026
Laboratory Automation & Robotics
Salesforce lands 140 life sciences clients, pitches ‘headless’ AI to pharma
Lana Keisha Jun 16, 2026
Advanced Materials Science
Engineered Metamaterials Breakthrough Unlocks Precision Control of Heat Transfer at the Nanoscale
Nila Kartika Wati Jun 16, 2026
Pharmaceutical R&D
AvenCell Therapeutics Unveils Promising Early Data for Switchable Allogeneic CAR-T Therapy in Relapsed/Refractory AML at EHA 2026
Teuku Ryan Jun 16, 2026

Copyright © 2025 | Powered by WordPress | News Gadgets by ThemeArile

  • Home
  • About Us
    • About Us
    • Affiliate Disclosure
    • Cookie Policy
    • Disclaimer
    • Privacy Policy
    • DMCA
    • Terms of Service
  • Contact Us
  • FAQ